Substituted benzosulphonamides

1. A compound of general formula (I):

in which:

R1 is a hydrogen atom or a fluorine atom;

R2 is a halogen atom or a C 2 -alkynyl or cyano group;

R3 is an —NH 2 , —NH(C 1 -C 6 -alkyl), —N(C 1 -C 6 -alkyl) 2 , —C 1 -C 6 -alkyl, or —C 3 -C 6 -cycloalkyl group;

R4 is an —NH 2 , —NH(C 1 -C 6 -alkyl), —N(C 1 -C 6 -alkyl) 2 , —C 1 -C 6 -alkyl, or —C 3 -C 6 -cycloalkyl group;

R5 is a hydrogen atom, a halogen atom, or a —C 1 -C 6 -alkyl or —O—C 1 -C 6 -alkyl group;

A is —(CH 2 ) n —, in which n=0, or 1;

or a tautomer, stereoisomer, N-oxide, salt, hydrate, or solvate thereof.

2. The compound according to claim 1 , wherein:

R1 is a hydrogen atom or a fluorine atom;

R2 is a fluorine atom or a C 2 -alkynyl or cyano group;

R3 is an —NH 2 , —NH(C 1 -C 6 -alkyl), —N(C 1 -C 6 -alkyl) 2 , —C 1 -C 6 -alkyl, or —C 3 -C 6 -cycloalkyl group;

R4 is an —NH 2 , —NH(C 1 -C 6 -alkyl), —N(C 1 -C 6 -alkyl) 2 , —C 1 -C 6 -alkyl, or —C 3 -C 6 -cycloalkyl group;

R5 is a hydrogen atom, a fluorine atom or a methyl group;

A is —(CH 2 ) n —, in which n=0, or 1;

or a tautomer, stereoisomer, N-oxide, salt, hydrate, or solvate thereof.

3. The compound according to claim 1 , wherein:

R1 is a hydrogen atom or a fluorine atom;

R2 is a fluorine atom or a C 2 -alkynyl or cyano group;

R3 is an —NH 2 , —NH(C 1 -C 6 -alkyl), —N(C 1 -C 6 -alkyl) 2 , —C 1 -C 6 -alkyl, or —C 3 -C 6 -cycloalkyl group;

R4 is an —NH 2 , methyl, ethyl, n-propyl, iso-propyl, cyclopropyl or cyclobutyl group;

R5 is a hydrogen atom, a fluorine atom or a methyl group;

A is —(CH 2 ) n —, in which n=0, or 1;

or a tautomer, stereoisomer, N-oxide, salt, hydrate, or solvate thereof.

4. The compound according to claim 1 , wherein:

R1 is a hydrogen atom or a fluorine atom;

R2 is a fluorine atom or a C 2 -alkynyl or cyano group;

R3 is an —NH 2 , methyl, ethyl, n-propyl, iso-propyl, cyclopropyl or cyclobutyl group;

R4 is an —NH 2 , methyl, ethyl, n-propyl, iso-propyl, cyclopropyl or cyclobutyl group;

R5 is a hydrogen atom, a fluorine atom or a methyl group;

A is —(CH 2 ) n —, in which n=0, or 1;

or a tautomer, stereoisomer, N-oxide, salt, hydrate, or solvate thereof.

5. The compound according to claim 1 , which is selected from the group consisting of:

N-(2-{3-[(ethylsulfonyl)amino]phenoxy}-4-fluoro-6-[(2-fluoro-4-iodophenyl)amino]phenyl)cyclopropanesulfonamide;

N-(3-{5-fluoro-3-[(2-fluoro-4-iodophenyl)amino]-2-[(methylsulfonyl)-amino]phenoxy}-phenyl)ethane-sulfonamide;

N-(3-{2-[(ethylsulfonyl)amino]-5-fluoro-3-[(2-fluoro-4-iodophenyl)amino]-phenoxy}phenyl)-ethanesulfonamide;

N-(2-{3-[(ethylsulfonyl)amino]phenoxy}-4-fluoro-6-[(2-fluoro-4-iodophenyl)amino]-phenyl)propane-2-sulfonamide;

N-(2-{3-[(ethylsulfonyl)amino]phenoxy}-4-fluoro-6-[(2-fluoro-4-iodophenyl)amino]-phenyl)cyclobutane-sulfonamide;

N-(3-{5-fluoro-3-[(2-fluoro-4-iodophenyl)amino]-2-(sulfamoylamino)phenoxy}phenyl)ethanesulfonamide;

N-(2-{3-[(ethylsulfonyl)amino]-2-methylphenoxy}-4-fluoro-6-[(2-fluoro-4-iodophenyl)amino]phenyl)cyclopropanesulfonamide;

N-(3-{5-fluoro-3-[(2-fluoro-4-iodophenyl)amino]-2-(sulfamoylamino)phenoxy}-2-methylphenyl)ethanesulfonamide;

N-(2-{3-[(ethylsulfonyl)amino]phenoxy}-6-[(4-ethynyl-2-fluorophenyl)amino]-4-fluorophenyl)cyclopropanesulfonamide;

N-(3-{3-[(4-ethynyl-2-fluorophenyl)amino]-5-fluoro-2-(sulfamoylamino)phenoxy}phenyl)ethanesulfonamide [Formic Acid salt];

N-{4-fluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-[3-(sulfamoylamino)phenoxy]phenyl}cyclopropanesulfonamide;

N-(4-fluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-{3-[(isopropylsulfonyl)amino]phenoxy}phenyl)cyclopropanesulfonamide;

N-(4-fluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-{3-[(methylsulfonyl)amino]phenoxy}phenyl)cyclopropanesulfonamide;

N-{4-fluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-[4-fluoro-3-(sulfamoylamino)phenoxy]phenyl}cyclopropanesulfonamide;

N-(5{2-[(cyclopropylsulfonyl)amino]-5-fluoro-3-[(2-fluoro-4-iodophenyl)amino]phenoxy}-2-fluorophenyl)cyclopropanesulfonamide;

N-(2-fluoro-5-{5-fluoro-3-[(2-fluoro-4-iodophenyl)amino]-2-(sulfamoylamino)phenoxy}phenyl)sulfuric diamide; and

N-(4-fluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-{3-[(sulfamoylamino)methyl]phenoxy}phenyl)cyclopropanesulfonamide.

6. A method of preparing a compound of general formula (I) according to claim 1 , said method comprising the step of allowing an intermediate compound of general formula (4):

in which R1, R2, R4, R5 and A are as defined in claim 1 ,

to react with a sulphonyl chloride of general formula E:

in which R3 is as defined in claim 1 ,

thereby giving a compound of general formula I:

in which R1, R2, R3, R4, R5 and A are as defined in claim 1 .

7. A method of preparing a compound of general formula (I) according to claim 1 , said method comprising the step of allowing an intermediate compound of general formula (8):

in which R1, R2, R3, R5 and A are as defined in claim 1 ,

to react with a sulphonyl chloride of general formula D:

in which R4 is as defined in claim 1 ,

thereby giving a compound of general formula I:

in which R1, R2, R3, R4, R5 and A are as defined in claim 1 .

8. A method of preparing a compound of general formula (Ic), said method comprising the step of allowing an intermediate compound of general formula (12):

in which R 1 , R 2 , R 3 , R 5 , and A are as defined in claim 1 , and PG represents an acid labile protecting group,

to react with an acid, thereby giving a compound of formula (Ic):

in which R 1 , R 2 , R 3 , R 5 and A are as defined in claim 1 .

9. A pharmaceutical composition comprising a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same, according to claim 1 , and a pharmaceutically acceptable diluent or carrier.

10. A pharmaceutical combination comprising:

one or more compounds of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same, according to claim 1 ;

and

one or more agents selected from: a taxane; an epothilone; Mitoxantrone; Prednisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2′-deoxyadenosine; Thioguanine; an anti-androgen; Bortezomib; a platinum derivative; Chlorambucil; Methotrexate; and Rituximab.

11. A method for the treatment of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, wherein the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by the mitogen-activated protein kinase (MEK-ERK) pathway, comprising administering to a human in need thereof a therapeutically acceptable amount of a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same, according to claim 1 .

12. The method according to claim 11 , wherein the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haemotological tumour, a solid tumour and/or metastases thereof.

13. The method according to claim 12 , wherein the haemotological tumour, solid tumour and/or metastases thereof is selected from leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours, brain tumours and brain metastases, tumours of the thorax, non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours, renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.